The pharma biotools sector—which encompasses technologies and services for drug discovery, clinical development, biopharmaceutical manufacturing, and diagnostics—is on pace for 513 VC deals in 2025, which is well above the previous annual record of 442. The sector has evolved from capital-intensive hardware providers to sophisticated platforms integrating digital technologies into wet-lab approaches. The new ability to operate software-as-a-service-like business models has led to the proliferation of early-stage startups, and investors are following.
Read the full article: PitchBook: Q3 2025 Pharma Biotools VC Trends //
Source: https://pitchbook.com/news/reports/q3-2025-pharma-biotools-vc-trends